Literature DB >> 30464698

Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia.

C Owen1, A S Gerrie2, V Banerji3, S Assouline4, C Chen5, K S Robinson6, E Lye7, G Fraser8.   

Abstract

Chronic lymphocytic leukemia (cll) is the most common adult leukemia in North America. In Canada, no unified national guideline exists for the front-line treatment of cll; provincial guidelines vary and are largely based on funding. A group of clinical experts from across Canada developed a national evidence-based treatment guideline to provide health care professionals with clear guidance on the first-line management of cll. Consensus recommendations based on available evidence are presented for the first-line treatment of cll.

Entities:  

Keywords:  Key Words Chronic lymphocytic leukemia; cll; fitness; prognosis; treatment

Mesh：

Year:  2018        PMID： 30464698      PMCID： PMC6209557          DOI： 10.3747/co.25.4092

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


  68 in total

1.  Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Authors:  Constantine S Tam; Susan O'Brien; William Wierda; Hagop Kantarjian; Sijin Wen; Kim-Anh Do; Deborah A Thomas; Jorge Cortes; Susan Lerner; Michael J Keating
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

2.  Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia.

Authors:  David Oscier; Claire Dearden; Efrem Eren; Efrem Erem; Christopher Fegan; George Follows; Peter Hillmen; Tim Illidge; Estella Matutes; Don W Milligan; Andrew Pettitt; Anna Schuh; Jennifer Wimperis
Journal:  Br J Haematol       Date:  2012-10-11       Impact factor: 6.998

3.  Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.

Authors:  M Magni; M Di Nicola; C Patti; R Scimè; A Mulè; A Rambaldi; T Intermesoli; P Viero; C Tarella; A Gueli; L Bergui; L Trentin; A Barzan; F Benedetti; A Ambrosetti; F Di Raimondo; A Chiarenza; G Parvis; A Billio; I Attolico; A Olivieri; M Montanari; C Carlo-Stella; P Matteucci; L Devizzi; A Guidetti; S Viviani; P Valagussa; A M Gianni
Journal:  Bone Marrow Transplant       Date:  2014-01-20       Impact factor: 5.483

4.  Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.

Authors:  G Dighiero; K Maloum; B Desablens; B Cazin; M Navarro; R Leblay; M Leporrier; J Jaubert; G Lepeu; B Dreyfus; J L Binet; P Travade
Journal:  N Engl J Med       Date:  1998-05-21       Impact factor: 91.245

5.  Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients.

Authors:  Massimo Gentile; Tait D Shanafelt; Davide Rossi; Luca Laurenti; Francesca R Mauro; Stefano Molica; Giovanna Cutrona; Giuseppina Uccello; Melissa Campanelli; Ernesto Vigna; Giovanni Tripepi; Kari G Chaffee; Sameer A Parikh; Sabrina Bossio; Anna Grazia Recchia; Idanna Innocenti; Raffaella Pasquale; Antonino Neri; Manlio Ferrarini; Gianluca Gaidano; Robin Foà; Fortunato Morabito
Journal:  Blood       Date:  2016-08-22       Impact factor: 22.113

Review 6.  Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.

Authors:  Michael Hallek
Journal:  Am J Hematol       Date:  2015-05       Impact factor: 10.047

7.  Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation.

Authors:  C Shustik; R Mick; R Silver; A Sawitsky; K Rai; L Shapiro
Journal:  Hematol Oncol       Date:  1988 Jan-Mar       Impact factor: 5.271

8.  Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.

Authors:  Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Bercedis L Peterson; John G Gribben; Vicki A Morrison; Kanti R Rai; Richard A Larson; John C Byrd
Journal:  J Clin Oncol       Date:  2011-02-14       Impact factor: 44.544

9.  Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.

Authors:  Andrew R Pettitt; Richard Jackson; Stacey Carruthers; James Dodd; Susanna Dodd; Melanie Oates; Gillian G Johnson; Anna Schuh; Estella Matutes; Claire E Dearden; Daniel Catovsky; John A Radford; Adrian Bloor; George A Follows; Stephen Devereux; Anton Kruger; Julie Blundell; Samir Agrawal; David Allsup; Stephen Proctor; Earnest Heartin; David Oscier; Terry J Hamblin; Andrew Rawstron; Peter Hillmen
Journal:  J Clin Oncol       Date:  2012-04-09       Impact factor: 44.544

10.  Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.

Authors:  Carmen Diana Herling; Marion Klaumünzer; Cristiano Krings Rocha; Janine Altmüller; Holger Thiele; Jasmin Bahlo; Sandra Kluth; Giuliano Crispatzu; Marco Herling; Joanna Schiller; Anja Engelke; Eugen Tausch; Hartmut Döhner; Kirsten Fischer; Valentin Goede; Peter Nürnberg; Hans Christian Reinhardt; Stephan Stilgenbauer; Michael Hallek; Karl-Anton Kreuzer
Journal:  Blood       Date:  2016-05-25       Impact factor: 22.113
View more
  2 in total

1.  Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-naïve chronic lymphocytic leukemia.

Authors:  V Banerji; P Anglin; A Christofides; S Doucette; P Laneuville
Journal:  Curr Oncol       Date:  2020-05-01       Impact factor: 3.677

2.  Examining Treatment Patterns and Real-World Outcomes in Chronic Lymphocytic Leukemia Using Administrative Data in Ontario.

Authors:  Soo Jin Seung; Manjusha Hurry; Shazia Hassan; Ashlie Elnoursi; Krystin A B Scheider; Dennis Wagner; Jonathan J Edwin; Andrew T W Aw
Journal:  Curr Oncol       Date:  2021-11-19       Impact factor: 3.677
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.